Journal
BRITISH JOURNAL OF CANCER
Volume 102, Issue 2, Pages 447-454Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bjc.6605338
Keywords
colorectal cancer; association; polymorphism
Categories
Funding
- Cancer Research UK
- European Union
- Instituto de Salud Carlos III [FIS 05/1006, 08/1359, 08/1635]
- European Commission [FP6 Food-CT-2006-036224]
- Genome Canada
- National Cancer Institute of Canada
- Ontario Institute for Cancer Research
- Academy of Finland [20062011]
- Sigrid Juselius Foundation
- Finnish Cancer Societies
- German Genome Network
- GACR [310/07/1430]
- Swedish Cancer Foundation
- Swedish Research Council
- Fondo de Investigacion Sanitaria [FIS 04/1126, 05/2031, 05/0071, 08/0025, 08/1276, 03-0070]
- Xunta de Galicia [PGIDIT07PXIB9101209PR]
- Fundacion de Investigacion Medica Mutua Madrilena
- Ministerio de Educacion y Ciencia [SAF 07-64873]
- Asociacion Espanola contra el Cancer
- Fundacion Olga Torres
- Instituto de Salud Carlos III
- NHMRC [489418]
- Ministry of Education, Culture, Sports, Sciences and Technology of the Japanese government
- Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom
- Cancer Research UK [11021] Funding Source: researchfish
- Cancer Research UK
- The Francis Crick Institute [10119] Funding Source: researchfish
- Cancer Research UK
- The Francis Crick Institute [10124] Funding Source: researchfish
- Medical Research Council [MC_U127527198] Funding Source: researchfish
- MRC [MC_U127527198] Funding Source: UKRI
Ask authors/readers for more resources
It is now recognised that a part of the inherited risk of colorectal cancer (CRC) can be explained by the co-inheritance of low-penetrance genetic variants. The accumulated experience to date in identifying these variants has served to highlight difficulties in conducting statistically and methodologically rigorous studies and follow-up analyses. The COGENT (COlorectal cancer GENeTics) consortium includes 20 research groups in Europe, Australia, the Americas, China and Japan. The overarching goal of COGENT is to identify and characterise low-penetrance susceptibility variants for CRC through association-based analyses. In this study, we review the rationale for identifying low-penetrance variants for CRC and our proposed strategy for establishing COGENT. British Journal of Cancer (2010) 102, 447-454. doi:10.1038/sj.bjc.6605338 www.bjcancer.com Published online 17 November 2009 (C) 2010 Cancer Research UK
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
